Annual Report 2024

3 Segment information

Segment information

 

 

Healthcare

 

Consumer & Industrial

 

Total medmix

millions of CHF

 

2024

 

2023

 

2024

 

2023

 

2024

 

2023

Revenue 1)

 

176.7

 

177.0

 

307.2

 

309.6

 

483.9

 

486.6

Segment cost of goods sold

 

–68.0

 

–69.7

 

–198.4

 

–200.5

 

–266.4

 

–270.2

Segment gross profit

 

108.7

 

107.3

 

108.8

 

109.0

 

217.5

 

216.4

Segment gross profit margin

 

61.5%

 

60.6%

 

35.4%

 

35.2%

 

45.0%

 

44.5%

1) Revenue from external customers.

Certain expenses are not attributable to a particular segment and are reported as a whole across the group irrespective of the segment. These expenses are presented in the following reconciliation statement.

Bridge from segment gross profit to operating income (EBIT)

millions of CHF

 

2024

 

2023

Segment gross profit

 

217.5

 

216.4

Other cost of goods sold

 

–57.8

 

–58.7

Gross profit

 

159.7

 

157.6

Operating expenses

 

–146.7

 

–141.7

Operating income (EBIT)

 

12.9

 

16.0

Information about reportable segments

Operating segments are determined based on the reports reviewed by the Board of Directors (BoD, chief operating decision maker) that are used to measure performance, make strategic decisions and allocate resources to the segments. The business is managed based on segments, and the reportable segments have been identified as disclosed below. The BoD assesses the performance of the two segments based on the segments’ revenue, gross profit and gross profit margin.

The BoD assesses the performance of the segments using alternative performance measures (APMs), which are derived from the financial statements prepared in accordance with IFRS Accounting Standards.

The APMs are prepared in addition to IFRS Accounting Standards to assist in comparability of information across periods and segments.

Revenue from external customers reported to the BoD is measured in a manner consistent with that in the income statement. There is no significant revenue between the segments. No individual customer represents a significant portion of the group’s revenue.

Healthcare

Through its well-known brands Haselmeier, Medmix, Mixpac and Transcodent, the Healthcare segment specializes in the design and production of innovative, high-precision delivery devices and services within the drug delivery, surgery and dental markets. Products include injection pens for subcutaneous delivery of drugs, surgical delivery devices focusing on trauma bone repair and wound-healing tissue treatment, and mixing, filling and delivery device systems for the dental consumable industry.

The segment’s IP-protected solutions make customers’ products precise, safe, unique and more sustainable, leveraging the business’s expertise in drug delivery, plastic-injection technology, molding and two-component mixing.

Consumer & Industrial

Through its well-known brands Mixpac, MK, Cox and Geka, the Consumer & Industrial segment specializes in the design and production of innovative, high-precision delivery devices and services within the Industry business unit, such as adhesives used in construction, electronics, automotive, aerospace and various industries, and consumer markets such as beauty and other microbrush applications. Products include hand-held mixing and dispensing delivery devices for two-component adhesives and sealants, mixing tips, cartridges, high-precision makeup applicators and microbrushes.

The segment’s IP-protected solutions make customers’ products precise, safe, unique and more sustainable, leveraging the business’s expertise in plastic injection molding, two-component mixing, fluid handling, material design and microbrushes.

Regional information

The allocation of assets is based on their geographical location. Non-current assets exclude non-current financial assets (other than investments in associates), deferred income tax assets and defined benefit assets. The allocation of revenue from external customers is based on the ship-to location defined by the group’s customer, which does not necessarily correspond with the location of the end-customer.

Non-current assets by region

millions of CHF

 

2024

 

2023

Europe, the Middle East and Africa

 

526.8

 

548.3

– thereof Germany

 

274.4

 

288.5

– thereof Switzerland

 

187.1

 

203.1

– thereof Spain

 

43.0

 

34.5

– thereof United Kingdom

 

17.3

 

18.3

 

 

 

 

 

Americas

 

67.7

 

55.4

– thereof USA

 

65.9

 

53.9

 

 

 

 

 

Asia-Pacific

 

56.5

 

56.5

– thereof China

 

55.6

 

56.1

 

 

 

 

 

Total non-current assets

 

651.0

 

660.2

Revenue by region

millions of CHF

 

2024

 

2023

Europe, the Middle East and Africa

 

285.4

 

298.2

– thereof Germany

 

108.2

 

99.2

– thereof Italy

 

42.7

 

51.6

– thereof France

 

26.0

 

32.6

– thereof United Kingdom

 

25.4

 

17.5

– thereof Switzerland

 

19.4

 

26.0

 

 

 

 

 

Americas

 

140.5

 

139.2

– thereof USA

 

120.0

 

113.9

 

 

 

 

 

Asia-Pacific

 

58.0

 

49.1

– thereof China

 

24.7

 

20.4

– thereof Japan

 

13.0

 

13.1

 

 

 

 

 

Total revenue

 

483.9

 

486.6

Business unit information

The following table shows the allocation of revenue from external customers by business unit:

Revenue by business unit

millions of CHF

 

2024

 

2023

Dental

 

115.6

 

106.2

Drug Delivery

 

43.4

 

53.6

Surgery

 

17.7

 

17.2

Total Healthcare

 

176.7

 

177.0

 

 

 

 

 

Industry

 

126.6

 

130.9

Beauty

 

180.6

 

178.6

Total Consumer & Industrial

 

307.2

 

309.6

 

 

 

 

 

Total revenue

 

483.9

 

486.6